Srikanth Pendyala, M.D., has been appointed as Chief Medical Officer of Infinimmune
Dr. Pendyala will lead clinical and regulatory strategy across Infinimmune's pipeline
He brings more than 25 years of experience in immunology and inflammation therapies
His role includes leading first-in-human trials of IFX-101 and IFX-201
Infinimmune is a biotechnology company specializing in antibody discovery and design
The company is based in Alameda, California